- Main
- News
News
Phase 1b clinical trial with HER-096 in Parkinson’s disease is ongoing.
The primary objective is to show that repeated subcutaneous doses of HER-096 are safe and well-tolerated in patients with Parkinson’s disease.
The Phase 1b clinical study has two parts:
- In Part 1, up to 12 healthy volunteer subjects will be dosed with a single dose for assessment of pharmacokinetic properties of HER-096.
- In Part 2, up to 28 patients with Parkinson’s disease will be dosed for 4 week, 2 doses per week with either HER-096 or placebo to study the safety and tolerability of repeated subcutaneous doses of HER-096. The aim is also to evaluate selected biomarkers and discover and identify novel biomarkers in the Parkinson’s patients. The recruitment of patients will start after completing the Part 1 of the study.
Researchers are using an advanced brain imaging method called MEG to understand why Parkinson’s drug levodopa doesn’t work equally well for everyone. By mapping patients’ brain signals before and after taking the drug, they discovered that it sometimes activates the wrong brain regions, dampening its helpful effects. This breakthrough could pave the way for personalized treatment strategies, ensuring patients receive medications that target the right areas of their brain more effectively.
Motor function was improved in experimental models, paving the way for further research in humans.
A decade-long quest revealed that a mis-folded SOD1 protein drives Parkinson’s. Re-balancing its copper chemistry in mice erased tremor-like symptoms, opening the door to human trials. Credit: Shutterstock
Groundbreaking research by the University of Sydney has identified a new brain protein involved in the development of Parkinson's disease and a way to modify it, paving the way for future treatments for the disease.


